Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Elanco Animal Health, with nine buy ratings, one strong buy, two holds and one sell. The average 12-month price target is $29.09, above the reported share price of $23.91.
• Elanco exceeded quarterly expectations, reporting $0.34 in EPS versus the $0.27 consensus and revenue of $1.37 billion versus $1.31 billion expected. Revenue increased 10.2% year over year, while full-year 2026 EPS guidance is $1.10–$1.16.
• Insiders have been buying shares, including the CFO’s purchase of 4,200 shares and a director’s purchase of 5,000 shares; insiders acquired 63,198 shares worth approximately $1.47 million over the past 90 days.

Shares of Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the thirteen analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $29.0909.

Several brokerages have issued reports on ELAN. JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the company an "overweight" rating in a research note on Thursday, May 7th. TD Cowen lifted their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, June 18th. Citigroup boosted their target price on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a "buy" rating in a research report on Thursday, May 7th. UBS Group increased their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Finally, Morgan Stanley increased their target price on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 22nd.

Elanco Animal Health Price Performance

ELAN stock opened at $23.91 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The firm has a market cap of $11.95 billion, a price-to-earnings ratio of -58.32, a PEG ratio of 1.43 and a beta of 1.68. The company's fifty day simple moving average is $24.63 and its 200 day simple moving average is $23.98. Elanco Animal Health has a 12-month low of $17.11 and a 12-month high of $27.98.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, topping analysts' consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The business's revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business posted $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, analysts expect that Elanco Animal Health will post 1.12 earnings per share for the current year.

Insider Activity

In related news, CFO Robert M. Vanhimbergen acquired 4,200 shares of the business's stock in a transaction dated Friday, August 7th. The shares were bought at an average price of $23.08 per share, with a total value of $96,936.00. Following the transaction, the chief financial officer directly owned 137,516 shares of the company's stock, valued at $3,173,869.28. This trade represents a 3.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Michael J. Harrington purchased 5,000 shares of the business's stock in a transaction on Wednesday, August 12th. The stock was purchased at an average price of $21.82 per share, for a total transaction of $109,100.00. Following the acquisition, the director owned 131,451 shares of the company's stock, valued at approximately $2,868,260.82. This represents a 3.95% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 63,198 shares of company stock valued at $1,473,109. Corporate insiders own 1.14% of the company's stock.

Hedge Funds Weigh In On Elanco Animal Health

Large investors have recently modified their holdings of the company. NewEdge Advisors LLC increased its stake in Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock valued at $25,000 after purchasing an additional 627 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Elanco Animal Health during the second quarter worth $38,000. Root Financial Partners LLC lifted its stake in shares of Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock valued at $40,000 after buying an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new position in shares of Elanco Animal Health in the fourth quarter valued at $41,000. Finally, Bessemer Group Inc. lifted its stake in shares of Elanco Animal Health by 33.2% in the first quarter. Bessemer Group Inc. now owns 2,105 shares of the company's stock valued at $50,000 after buying an additional 525 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source